SAGA Diagnostics

No new round recorded in 64 months.

1. 29 Jun 2021

   Series A

   €10.4M

   Cumulative €10.4M

Amounts in EUR, converted at the ECB rate on the event date. Funding totals exclude debt, grants and state aid; rounds whose instrument is not yet established are still counted. Every figure links to its source.

• Exit16 Apr 2026EUR 535.5M

  SAGA Diagnostics, acquisition by Roche for EUR 535.5M.

  Acquisition

  ▸Source: fiercebiotech.com

  Read at fiercebiotech.com

• Funding29 Jun 2021EUR 10.4M

  SAGA Diagnostics raised a SEK 106 million (about EUR 10.5 million) Series A2 round led by Segulah Medical Acceleration and the Sciety investment syndicate with support from existing shareholder Hadean Ventures, to commercialize its liquid biopsy cancer tests. This predates the April 2026 Foundation Medicine/Roche acquisition already on record.

  ▸Source: prnewswire.com

  Read at prnewswire.com

• Anthony George

  Co-founder and CTO

• Lao Saal

  Founder, now COO and board member (was CEO 2016-2021)

• Roopom Banerjee

  Executive Chairman

What does SAGA Diagnostics do?

Swedish cancer liquid-biopsy and MRD company (Pathlight platform; ultrasensitive ctDNA detection). Spinout of Lund University 2014. HQ now Morrisville NC; set to be acquired by Roche.

When was SAGA Diagnostics founded?

SAGA Diagnostics was founded in 2014.

Where is SAGA Diagnostics headquartered?

SAGA Diagnostics is headquartered in Lund, Sweden.

How much funding has SAGA Diagnostics raised?

SAGA Diagnostics has raised €10.4M (across 1 round · last 29 Jun 2021).

What was SAGA Diagnostics's latest funding round?

SAGA Diagnostics's most recent disclosed round was a series_a round of €10.4M, announced 29 June 2021.